Provided by Tiger Trade Technology Pte. Ltd.

Cytokinetics

74.11
-1.2400-1.65%
Pre-market: 74.560.4500+0.61%07:21 EDT
Volume:1.42M
Turnover:105.44M
Market Cap:10.30B
PE:-10.32
High:74.89
Open:74.31
Low:73.52
Close:75.35
52wk High:88.31
52wk Low:47.22
Shares:139.02M
Float Shares:138.02M
Volume Ratio:0.87
T/O Rate:1.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.1827
EPS(LYR):-6.5400
ROE:-572.15%
ROA:-28.09%
PB:-59.39
PE(LYR):-11.33

Loading ...

Cytokinetics Q2 Operating Expenses USD 207.796 Million

THOMSON REUTERS
·
Aug 07

Cytokinetics Q2 Basic EPS USD -1.5

THOMSON REUTERS
·
Aug 07

Cytokinetics Q2 R&D Revenue USD 25.334 Million

THOMSON REUTERS
·
Aug 07

Cytokinetics Inc Q2 Shr View $-1.64

THOMSON REUTERS
·
Aug 07

Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update

THOMSON REUTERS
·
Aug 07

Opus, Cytokinetics, Albertsons, Weatherford, Paysign Shock

TIPRANKS
·
Aug 01

Top Cytokinetics Executive Makes Eye-Catching Move With Insider Stock Sale

TIPRANKS
·
Jul 31

Earning Preview: Cytokinetics this quarter’s revenue is expected to increase by 629.37%, and institutional views are bullish

Earnings Agent
·
Jul 31

Cytokinetics EVP, Chief Commercial Officer Andrew Callos Sells 14,000 Common Shares for $1.12 Million

Reuters
·
Jul 31

Cytokinetics Wins UK Approval, NICE Backing for Heart Disease Drug

Reuters
·
Jul 30

Cytokinetics announces MHRA authorization for Myqorzo

TIPRANKS
·
Jul 30

Cytokinetics Says UK MHRA Approves Myqorzo for Obstructive Hypertrophic Cardiomyopathy

Reuters
·
Jul 30

Cytokinetics Announces Mhra Marketing Authorisation for Myqorzo®▼ (Aficamten) and Positive Guidance from Nice for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales

THOMSON REUTERS
·
Jul 30

UK's Mhra: Confidential Discount Has Been Agreed with Cytokinetics, to Make Aficamten Available to Nhs at Reduced Cost

THOMSON REUTERS
·
Jul 30

Is Cytokinetics (CYTK) Cheap Or Has Its Cardiac Growth Story Already Been Priced In?

Simply Wall St.
·
Jul 28

Top Cytokinetics Insider Makes Major Move in High-Value Stock Sale

TIPRANKS
·
Jul 28

Cytokinetics CEO Robert I. Blum Disposes of 7,500 Common Shares for $606,525

Reuters
·
Jul 28

Travelers, TransDigm, Cytokinetics, Global-e, Crescent Shock Moves

TIPRANKS
·
Jul 25

Top Cytokinetics Executive Makes Notable Insider Stock Move

TIPRANKS
·
Jul 24

Cytokinetics EVP R&D Malik Fady Ibraham Disposes of 3,500 Common Shares for $282,065

Reuters
·
Jul 24